文献速递乳腺癌

阿替利珠单抗联合卡铂治疗转移性三阴性乳腺癌患者的生存结局:TBCRC 043 2期随机临床试验

Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项2期随机临床试验在6个中心纳入106例转移性三阴性乳腺癌女性患者,随机接受卡铂单药或卡铂联合阿替利珠单抗治疗。联合组无进展生存期(HR 0.66,95%CI 0.44-1.01,P=0.05)从2.2个月延长至4.1个月,总生存期(HR 0.60,95%CI 0.37-0.96,P=0.03)从8.6个月延长至12.6个月,客观缓解率从8.0%提高至30.4%。

要点

  • 卡铂联合阿替利珠单抗较卡铂单药改善转移性三阴性乳腺癌的无进展生存期(HR 0.66,95%CI 0.44-1.01,P=0.05)。
  • 联合组总生存期(HR 0.60,95%CI 0.37-0.96,P=0.03)从8.6个月延长至12.6个月。
  • PD-L1阳性肿瘤并未从联合阿替利珠单抗中获得更多获益(HR 0.62,95%CI 0.23-1.65,P=0.35)。

核心结论

  • 在转移性三阴性乳腺癌患者中,卡铂联合阿替利珠单抗较卡铂单药显著改善生存,且与PD-L1状态无关。
  • 肿瘤浸润淋巴细胞增高、突变负荷较高、肥胖及治疗中血糖水平升高与联合治疗组疾病进展风险降低相关。

研究设计与样本

  • 这项2期随机临床试验于2017年8月至2021年6月在6个中心开展。
  • 106例转移性三阴性乳腺癌女性患者随机接受卡铂(AUC 6)单药(n=50)或卡铂联合阿替利珠单抗1200 mg每3周一次(n=56),直至疾病进展或不可接受的毒性,随访3年。
  • 主要终点为研究者评估的无进展生存期,次要终点包括客观缓解率、临床获益率和总生存期。

主要发现

  • 联合组无进展生存期中位值从2.2个月延长至4.1个月(HR 0.66,95%CI 0.44-1.01,P=0.05)。
  • 联合组客观缓解率从8.0%(95%CI 3.2%-18.8%)提高至30.4%(95%CI 19.9%-43.3%)。
  • 联合组6个月临床获益率从18.0%(95%CI 9.8%-30.1%)提高至37.5%(95%CI 26.0%-50.6%)。
  • 联合组总生存期中位值从8.6个月延长至12.6个月(HR 0.60,95%CI 0.37-0.96,P=0.03)。
  • PD-L1阳性肿瘤亚组未从联合阿替利珠单抗中更多获益(HR 0.62,95%CI 0.23-1.65,P=0.35)。

关键数值与推荐

  • 高肿瘤浸润淋巴细胞者联合治疗获益更大(HR 0.12,95%CI 0.30-0.50)。
  • 高突变负荷者联合治疗获益更大(HR 0.50,95%CI 0.23-1.06)。
  • 既往接受过化疗者联合治疗获益更大(HR 0.59,95%CI 0.36-0.95)。
  • 肥胖及治疗中血糖水平超过125 mg/dL者联合治疗组无进展生存期更优(HR 0.35,95%CI 0.10-1.80)。
  • 各三阴性乳腺癌亚型均从联合阿替利珠单抗中获益,但管腔雄激素受体亚型除外。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Agents targeting programmed death ligand 1 (PD-L1) have demonstrated efficacy in triple-negative breast cancer (TNBC) when combined with chemotherapy and are now the standard of care in patients with PD-L1-positive metastatic disease. In contrast to microtubule-targeting agents, the effect of combining platinum compounds with programmed cell death 1 (PD-1)/PD-L1 immunotherapy has not been extensively determined. OBJECTIVE: To evaluate the efficacy of atezolizumab with carboplatin in patients with metastatic TNBC. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial was conducted in 6 centers from August 2017 to June 2021. INTERVENTIONS: Patients with metastatic TNBC were randomized to receive carboplatin area under the curve (AUC) 6 alone or with atezolizumab, 1200 mg, every 3 weeks until disease progression or unacceptable toxic effects with a 3-year duration of follow-up. MAIN OUTCOME AND MEASURES: The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included overall response rate (ORR), clinical benefit rate (CBR), and overall survival (OS). Other objectives included correlation of response with tumor PD-L1 levels, tumor-infiltrating lymphocytes (TILs), tumor DNA- and RNA-sequenced biomarkers, TNBC subtyping, and multiplex analyses of immune markers. RESULTS: All 106 patients with metastatic TNBC who were enrolled were female with a mean (range) age of 55 (27-79) years, of which 12 (19%) identified as African American/Black, 1 (1%) as Asian, 73 (69%) as White, and 11 (10%) as unknown. Patients were randomized and received either carboplatin (n = 50) or carboplatin and atezolizumab (n = 56). The combination improved PFS (hazard ratio [HR], 0.66; 95% CI, 0.44-1.01; P = .05) from a median of 2.2 to 4.1 months, increased ORR from 8.0% (95% CI, 3.2%-18.8%) to 30.4% (95% CI, 19.9%-43.3%), increased CBR at 6 months from 18.0% (95% CI, 9.8%-30.1%) to 37.5% (95% CI, 26.0%-50.6%), and improved OS (HR, 0.60; 95% CI, 0.37-0.96; P = .03) from a median of 8.6 to 12.6 months. Subgroup analysis showed PD-L1-positive tumors did not benefit more from adding atezolizumab (HR, 0.62; 95% CI, 0.23-1.65; P = .35). Patients with high TILs (HR, 0.12; 95% CI, 0.30-0.50), high mutation burden (HR, 0.50; 95% CI, 0.23-1.06), and prior chemotherapy (HR, 0.59; 95% CI, 0.36-0.95) received greater benefit on the combination. Patients with obesity and patients with more than 125 mg/dL on-treatment blood glucose levels were associated with better PFS (HR, 0.35; 95% CI, 0.10-1.80) on the combination. TNBC subtypes benefited from adding atezolizumab, except the luminal androgen receptor subtype. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the addition of atezolizumab to carboplatin significantly improved survival of patients with metastatic TNBC regardless of PD-L1 status. Further, lower risk of disease progression was associated with increased TILs, higher mutation burden, obesity, and uncontrolled blood glucose levels. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03206203.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Lehmann BD, Abramson VG, Dees EC, et al. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38095878. doi:10.1001/jamaoncol.2023.5424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。